Anti-Rheumatic Rx

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has provided much-needed reassuring answers.

Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com Listen by Clicking below: 1. EULAR2021 - Day2a 2. EULAR2021 - Day2b

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.